Novavax (NVAX) stock rose 11.4% on high volume following an 8-session decline.

From Nasdaq: 2025-04-07 03:27:00

Novavax (NVAX) shares rose 11.4% to $6.24, driven by high volume, following an 8-session decline. The company is expected to report a quarterly loss of $0.43 per share, with revenues of $72.27 million, down 23% from last year. Earnings estimate revisions suggest potential price appreciation for NVAX.

Travere Therapeutics (TVTX) closed 9.5% lower at $14.99, with a consensus EPS estimate of -$0.54 for the upcoming report. The stock has returned -12.6% in the past month and holds a Zacks Rank of #3 (Hold). Zacks Research Chief highlights a top stock with the potential to double in value, emphasizing innovation and growth opportunities.



Read more at Nasdaq: Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?